OBJECTIVE
To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent challenges; and generic drug penetration.
METHODS
This study used IMS Health National Sales Perspectives(TM) US data to calculate MEPs...
